A Study to Evaluate the Safety and Efficacy of Intracranial Venous Blood Sampling for Liquid Biopsy in the Diagnosis of Brain Cancers
2 other identifiers
observational
20
1 country
1
Brief Summary
To learn if drawing blood directly from veins inside the brain is safe and can effectively provide the same kind of detailed information about high-grade glioma as traditional surgical biopsy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Aug 2026
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 9, 2026
CompletedFirst Posted
Study publicly available on registry
March 12, 2026
CompletedStudy Start
First participant enrolled
August 19, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2027
Study Completion
Last participant's last visit for all outcomes
May 1, 2029
March 19, 2026
March 1, 2026
9 months
March 9, 2026
March 18, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
safety and adverse events (AEs).
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Through study completion; an average of 1 year
Study Arms (1)
Intracranial Venous Blood Sampling With BBB Disruption
Comparisons will be made between the peripheral, intracranial venous blood and intracranial arterial blood, before and after BBB disruption to evaluate the amount of ctDNA and the degree of concordance between molecular markers for tumor diagnosis.
Interventions
Eligibility Criteria
MD Anderson Cancer Center
You may not qualify if:
- Subjects with suspected glioma or other brain cancers who do not have a tissue diagnosis and no surgical biopsy or resection is anticipated.
- Subjects in whom diagnostic cerebral angiogram is contra-indicated defined as:
- Severe contrast allergy
- Acute/chronic renal dysfunction with eGFR \< 45 ml/min and Cr ≤ 1.5 mg/dL
- For participants undergoing surgery, refractory coagulopathy or thrombocytopenia which cannot be corrected defined as:
- Platelets ≤100,000/mcL
- International Normalized Ratio ≤ 1.7
- Subjects that have a known high risk in monitored anesthetic care or general anesthesia assessed by the treating physician.
- Anatomic considerations: based on cross-sectional imaging such as CT angiogram of the head and neck, the anatomy for arterial and venous vascular access is deemed unsuitable for endovascular access such as high-grade carotid artery stenosis, absent or occluded internal jugular veins, sigmoid sinuses and/or transverse sinuses.
- Participants with clinical cerebral edema evidenced from altered mental status
- Pregnant women due to risk of radiation exposure to the fetus, as determined by pregnancy urinalysis or serum analysis test during screening.
- Subjects with psychiatric illness/social situations that would limit compliance with study requirements at the physician's discretion.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Christopher C Young, MD
M.D. Anderson Cancer Center
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 9, 2026
First Posted
March 12, 2026
Study Start (Estimated)
August 19, 2026
Primary Completion (Estimated)
May 1, 2027
Study Completion (Estimated)
May 1, 2029
Last Updated
March 19, 2026
Record last verified: 2026-03